Cargando…

SAT420 Bone Health In Transgender People

Disclosure: G. Grande: None. C. Ceolin: None. B. Vescovi: None. M. Dall’Agnol: None. C. Ziliotto: None. S. Pasqualini: None. G. Petre: None. A. Scala: None. S. Giannini: None. V. Camozzi: None. A. Bertocco: None. G. Sergi: None. A. Ferlin: None. A. Garolla: None. In transgender subjects, worse Bone...

Descripción completa

Detalles Bibliográficos
Autores principales: Grande, Giuseppe, Ceolin, Chiara, Vescovi, Beatrice, Dall'Agnol, Martina, Ziliotto, Chiara, Pasqualini, Sara, Petre, Gabriel Cosmin, Scala, Alberto, Giannini, Sandro, Camozzi, Valentina, Bertocco, Anna, Sergi, Giuseppe, Ferlin, Alberto, Garolla, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554668/
http://dx.doi.org/10.1210/jendso/bvad114.2091
_version_ 1785116467580108800
author Grande, Giuseppe
Ceolin, Chiara
Vescovi, Beatrice
Dall'Agnol, Martina
Ziliotto, Chiara
Pasqualini, Sara
Petre, Gabriel Cosmin
Scala, Alberto
Giannini, Sandro
Camozzi, Valentina
Bertocco, Anna
Sergi, Giuseppe
Ferlin, Alberto
Garolla, Andrea
author_facet Grande, Giuseppe
Ceolin, Chiara
Vescovi, Beatrice
Dall'Agnol, Martina
Ziliotto, Chiara
Pasqualini, Sara
Petre, Gabriel Cosmin
Scala, Alberto
Giannini, Sandro
Camozzi, Valentina
Bertocco, Anna
Sergi, Giuseppe
Ferlin, Alberto
Garolla, Andrea
author_sort Grande, Giuseppe
collection PubMed
description Disclosure: G. Grande: None. C. Ceolin: None. B. Vescovi: None. M. Dall’Agnol: None. C. Ziliotto: None. S. Pasqualini: None. G. Petre: None. A. Scala: None. S. Giannini: None. V. Camozzi: None. A. Bertocco: None. G. Sergi: None. A. Ferlin: None. A. Garolla: None. In transgender subjects, worse Bone Mineral Density (BMD) values were observed when compared to cisgender controls before initiating Gender-Affirming Hormonal Therapy (GAHT). The reasons have not yet been fully clarified. In this study we analyzed bone metabolism and body composition in a population of transgender people before initiating GAHT, and their possible correlation with endocrine profile, mental health, and lifestyle habits. Medical data, phosphocalcic metabolism and hormonal parameters, lumbar and femoral bone mineral density, body composition, strength and psychological well-being (by Patient Health Questionnaire-9-PHQ-9 and Perceived Stress Scale-PSS questionnaires), were collected in a sample of 32 transgender people before GAHT initiation and 32 cisgender controls. Assigned Female At Birth (AFAB) transgender people presented worse Z-score values at total hip and neck femoral sites (-0.52±0.94 vs 0.15±0.82, and -0.37±0.79 vs 0.19±0.66, p=0.04 respectively), while in Assigned Male At Birth (AMAB) transgender people also lumbar sites were compromised in comparison to cisgender controls. No significant difference in phospho-calcium metabolism (calcium, phosphate, PTH and vitamin D) or hormonal profile (Testosterone, estradiol, LH, FSH) was found between the transgender and the cisgender group. PHQ-9 (a questionnaire to screen for depression) scores were higher in the transgender population than cisgender controls (9.35±7.41 vs 4.08±3.14, p=0.03 in AFAB and 9.54±5.45 vs 4.46±3.59, p=0.02 in AMAB transgender people). Multiple regression analysis identified PSS (a tool to assess stress levels and identify which situations are perceived as stressful) score as an independent predictor of total femur BMD, explaining about 54% of the variance. Transgender people before GAHT have worse bone health than cisgender subjects. In particular, BMD was reduced at the hip and in AMAB even at lumbar site. The reduction in bone mass before GAHT seems independent by hormonal and phospho-calcic profile and associated mostly with psychological status. Further study will clarify the specific pathogenetic mechanisms involved in bone growth in transgender people. However, according to our evidences, the psychological stress might influence negatively lifestyle habits therefore being involved in reduced bone health. Early lifestyle and psychological interventions might so be beneficial also for bone health in the transgender population. Presentation: Saturday, June 17, 2023
format Online
Article
Text
id pubmed-10554668
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105546682023-10-06 SAT420 Bone Health In Transgender People Grande, Giuseppe Ceolin, Chiara Vescovi, Beatrice Dall'Agnol, Martina Ziliotto, Chiara Pasqualini, Sara Petre, Gabriel Cosmin Scala, Alberto Giannini, Sandro Camozzi, Valentina Bertocco, Anna Sergi, Giuseppe Ferlin, Alberto Garolla, Andrea J Endocr Soc Transgender Medicine Disclosure: G. Grande: None. C. Ceolin: None. B. Vescovi: None. M. Dall’Agnol: None. C. Ziliotto: None. S. Pasqualini: None. G. Petre: None. A. Scala: None. S. Giannini: None. V. Camozzi: None. A. Bertocco: None. G. Sergi: None. A. Ferlin: None. A. Garolla: None. In transgender subjects, worse Bone Mineral Density (BMD) values were observed when compared to cisgender controls before initiating Gender-Affirming Hormonal Therapy (GAHT). The reasons have not yet been fully clarified. In this study we analyzed bone metabolism and body composition in a population of transgender people before initiating GAHT, and their possible correlation with endocrine profile, mental health, and lifestyle habits. Medical data, phosphocalcic metabolism and hormonal parameters, lumbar and femoral bone mineral density, body composition, strength and psychological well-being (by Patient Health Questionnaire-9-PHQ-9 and Perceived Stress Scale-PSS questionnaires), were collected in a sample of 32 transgender people before GAHT initiation and 32 cisgender controls. Assigned Female At Birth (AFAB) transgender people presented worse Z-score values at total hip and neck femoral sites (-0.52±0.94 vs 0.15±0.82, and -0.37±0.79 vs 0.19±0.66, p=0.04 respectively), while in Assigned Male At Birth (AMAB) transgender people also lumbar sites were compromised in comparison to cisgender controls. No significant difference in phospho-calcium metabolism (calcium, phosphate, PTH and vitamin D) or hormonal profile (Testosterone, estradiol, LH, FSH) was found between the transgender and the cisgender group. PHQ-9 (a questionnaire to screen for depression) scores were higher in the transgender population than cisgender controls (9.35±7.41 vs 4.08±3.14, p=0.03 in AFAB and 9.54±5.45 vs 4.46±3.59, p=0.02 in AMAB transgender people). Multiple regression analysis identified PSS (a tool to assess stress levels and identify which situations are perceived as stressful) score as an independent predictor of total femur BMD, explaining about 54% of the variance. Transgender people before GAHT have worse bone health than cisgender subjects. In particular, BMD was reduced at the hip and in AMAB even at lumbar site. The reduction in bone mass before GAHT seems independent by hormonal and phospho-calcic profile and associated mostly with psychological status. Further study will clarify the specific pathogenetic mechanisms involved in bone growth in transgender people. However, according to our evidences, the psychological stress might influence negatively lifestyle habits therefore being involved in reduced bone health. Early lifestyle and psychological interventions might so be beneficial also for bone health in the transgender population. Presentation: Saturday, June 17, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10554668/ http://dx.doi.org/10.1210/jendso/bvad114.2091 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Transgender Medicine
Grande, Giuseppe
Ceolin, Chiara
Vescovi, Beatrice
Dall'Agnol, Martina
Ziliotto, Chiara
Pasqualini, Sara
Petre, Gabriel Cosmin
Scala, Alberto
Giannini, Sandro
Camozzi, Valentina
Bertocco, Anna
Sergi, Giuseppe
Ferlin, Alberto
Garolla, Andrea
SAT420 Bone Health In Transgender People
title SAT420 Bone Health In Transgender People
title_full SAT420 Bone Health In Transgender People
title_fullStr SAT420 Bone Health In Transgender People
title_full_unstemmed SAT420 Bone Health In Transgender People
title_short SAT420 Bone Health In Transgender People
title_sort sat420 bone health in transgender people
topic Transgender Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554668/
http://dx.doi.org/10.1210/jendso/bvad114.2091
work_keys_str_mv AT grandegiuseppe sat420bonehealthintransgenderpeople
AT ceolinchiara sat420bonehealthintransgenderpeople
AT vescovibeatrice sat420bonehealthintransgenderpeople
AT dallagnolmartina sat420bonehealthintransgenderpeople
AT ziliottochiara sat420bonehealthintransgenderpeople
AT pasqualinisara sat420bonehealthintransgenderpeople
AT petregabrielcosmin sat420bonehealthintransgenderpeople
AT scalaalberto sat420bonehealthintransgenderpeople
AT gianninisandro sat420bonehealthintransgenderpeople
AT camozzivalentina sat420bonehealthintransgenderpeople
AT bertoccoanna sat420bonehealthintransgenderpeople
AT sergigiuseppe sat420bonehealthintransgenderpeople
AT ferlinalberto sat420bonehealthintransgenderpeople
AT garollaandrea sat420bonehealthintransgenderpeople